| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |